Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer

被引：6

作者：

Sekine, I. ^{[1
]}

Nokihara, H. ^{[1
]}

Takeda, K. ^{[2
]}

Nishiwaki, Y. ^{[3
]}

Nakagawa, K. ^{[4
]}

Isobe, H. ^{[5
]}

Mori, K. ^{[6
]}

Matsui, K. ^{[7
]}

Saijo, N. ^{[3
]}

Tamura, T. ^{[1
]}

机构：

[1] Natl Canc Ctr, Div Internal Med & Thorac Oncol, Tokyo 1040045, Japan

[2] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan

[3] Natl Canc Ctr Hosp, Div Thorac Oncol, Kashiwa, Chiba, Japan

[4] Kinki Univ, Sch Med, Dept Med Oncol, Sayama, Osaka, Japan

[5] Natl Hosp Org Hokkaido Canc Ctr, Dept Pulm Dis, Sapporo, Hokkaido, Japan

[6] Tochigi Prefectural Canc Ctr, Utsunomiya, Tochigi, Japan

[7] Osaka Prefectural Med Ctr Respirat & Allergic Dis, Dept Internal Med, Habikino, Japan

来源：

BRITISH JOURNAL OF CANCER | 2008年 / 98卷 / 04期

关键词：

small-cell lung cancer; chemotherapy; irinotecan; etoposide; three drug combination;

D O I：

10.1038/sj.bjc.6604233

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mgm(-2) on days 1 and 8 and cisplatin 60 mgm(-2) on day 1 with (n = 55) or without (n = 54) etoposide 50 mgm(-2) on days 1-3 with granulocyte colony-stimulating factor support repeated every 3 weeks for four cycles. The triplet regimen was too toxic to be considered for further studies.

引用

页码：693 / 696

页数：4

共 14 条

[1]

Armitage P, 2002, STAT METHODS MED RES, P568

[2] RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, AND VINCRISTINE VERSUS CISPLATIN AND ETOPOSIDE VERSUS ALTERNATION OF THESE REGIMENS IN SMALL-CELL LUNG-CANCER [J].

FUKUOKA, M ;

FURUSE, K ;

SAIJO, N ;

NISHIWAKI, Y ;

IKEGAMI, H ;

TAMURA, T ;

SHIMOYAMA, M ;

SUEMASU, K .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (12) :855-861

[3] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer [J].

Hanna, N ;

Bunn, PA ;

Langer, C ;

Einhorn, L ;

Guthrie, T ;

Beck, T ;

Ansar, R ;

Ellis, P ;

Byrne, M ;

Morrison, M ;

Hariharan, S ;

Wang, B ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2038-2043

[4] THE CALCULATION OF RECEIVED DOSE INTENSITY [J].

HRYNIUK, WM ;

GOODYEAR, M .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :1935-1937

[5] Small-cell lung cancer [J].

Jackman, DM ;

Johnson, BE .

LANCET, 2005, 366 (9494) :1385-1396

[6] SELECTION DESIGNS FOR PILOT-STUDIES BASED ON SURVIVAL [J].

LIU, PY ;

DAHLBERG, S ;

CROWLEY, J .

BIOMETRICS, 1993, 49 (02) :391-398

[7] CISPLATIN PLUS ETOPOSIDE WITH AND WITHOUT IFOSFAMIDE IN EXTENSIVE SMALL-CELL LUNG-CANCER - A HOOSIER ONCOLOGY GROUP-STUDY [J].

LOEHRER, PJ ;

ANSARI, R ;

GONIN, R ;

MONACO, F ;

FISHER, W ;

SANDLER, A ;

EINHORN, LH .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2594-2599

[8] A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer [J].

Mavroudis, D ;

Papadakis, E ;

Veslemes, M ;

Tsiafaki, X ;

Stavrakakis, J ;

Kouroussis, C ;

Kakolyris, S ;

Bania, E ;

Jordanoglou, J ;

Agelidou, M ;

Vlachonicolis, J ;

Georgoulias, V .

ANNALS OF ONCOLOGY, 2001, 12 (04) :463-470

[9] Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and leukemia group B trial 9732 [J].

Niell, HB ;

Herndon, JE ;

Miller, AA ;

Watson, DM ;

Sandler, AB ;

Kelly, K ;

Marks, RS ;

Perry, MC ;

Ansari, RH ;

Otterson, G ;

Ellerton, J ;

Vokes, EE ;

Green, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) :3752-3759

[10] Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer [J].

Noda, W ;

Nishiwaki, Y ;

Kawahara, M ;

Negoro, S ;

Sugiura, T ;

Yokoyama, A ;

Fukuoka, M ;

Mori, K ;

Watanabe, K ;

Tamura, T ;

Yamamoto, S ;

Saijo, N .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (02) :85-91

← 1 2 →